Releases
SABSW
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest SAB BIOTHERAPEUTICS INC (SABSW) stock and general news. This information may help you make smarter investment decisions.
About SABSW
SAb Biotherapeutics, Inc., formerly Big Cypress Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The Company is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.